The most commonly used dynamin inhibitors have revealed off-target effects in dynamin triple knockout cells [98], warranting future development of isoform-specific inhibitors for dynamin as potential therapeutics for successful anti-cancer treatment. This evidence concerns the gene DNM1 and cancer.